Log in

NASDAQ:PODD - Insulet Stock Price, Forecast & News

$212.32
+6.91 (+3.36 %)
(As of 02/17/2020 06:00 AM ET)
Add
Today's Range
$205.62
Now: $212.32
$212.85
50-Day Range
$169.34
MA: $187.93
$212.32
52-Week Range
$80.43
Now: $212.32
$212.85
Volume1.00 million shs
Average VolumeN/A
Market CapitalizationN/A
P/E Ratio816.65
Dividend YieldN/A
BetaN/A
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryHealth Care Equipment
SectorN/A
Current SymbolNASDAQ:PODD
CUSIP45784P10
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees1,169
Next Earnings Date2/25/2020 (Confirmed)
OptionableOptionable

Receive PODD News and Ratings via Email

Sign-up to receive the latest news and ratings for PODD and its competitors with MarketBeat's FREE daily newsletter.


Insulet (NASDAQ:PODD) Frequently Asked Questions

What is Insulet's stock symbol?

Insulet trades on the NASDAQ under the ticker symbol "PODD."

How were Insulet's earnings last quarter?

Insulet Co. (NASDAQ:PODD) posted its quarterly earnings results on Tuesday, November, 5th. The medical instruments supplier reported $0.01 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.03 by $0.02. The medical instruments supplier earned $192.12 million during the quarter, compared to analysts' expectations of $179.50 million. The company's revenue for the quarter was up 27.2% compared to the same quarter last year. During the same period in the previous year, the business posted $0.03 earnings per share. View Insulet's Earnings History.

When is Insulet's next earnings date?

Insulet is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Insulet.

How can I listen to Insulet's earnings call?

Insulet will be holding an earnings conference call on Tuesday, February 25th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What price target have analysts set for PODD?

17 analysts have issued 12-month price targets for Insulet's shares. Their forecasts range from $100.00 to $213.00. On average, they anticipate Insulet's stock price to reach $162.06 in the next year. This suggests that the stock has a possible downside of 23.7%. View Analyst Price Targets for Insulet.

What is the consensus analysts' recommendation for Insulet?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 1 sell rating, 8 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Insulet.

Has Insulet been receiving favorable news coverage?

News articles about PODD stock have been trending somewhat positive on Monday, according to InfoTrie. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Insulet earned a media sentiment score of 1.8 on InfoTrie's scale. They also gave media coverage about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Insulet.

Who are some of Insulet's key competitors?

What other stocks do shareholders of Insulet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include Alibaba Group (BABA), Netflix (NFLX), NVIDIA (NVDA), DexCom (DXCM), Splunk (SPLK), Tandem Diabetes Care (TNDM), Adobe (ADBE), Roku (ROKU), salesforce.com (CRM) and Veeva Systems (VEEV).

Who are Insulet's key executives?

Insulet's management team includes the folowing people:
  • Ms. Shacey Petrovic, Pres, CEO & Director (Age 45)
  • Mr. Charles Alpuche, Exec. VP & COO (Age 59)
  • Mr. Bret Christensen, Exec. VP & Chief Commercial Officer (Age 47)
  • Mr. Patrick J. Sullivan, Consultant (Age 67)
  • Mr. Michael L. Levitz, Advisor (Age 45)

Who are Insulet's major shareholders?

Insulet's stock is owned by many different of institutional and retail investors. Top institutional investors include William Blair Investment Management LLC (2.59%), Fred Alger Management LLC (2.34%), Eagle Asset Management Inc. (0.99%), Lord Abbett & CO. LLC (0.88%), Renaissance Technologies LLC (0.81%) and Bank of New York Mellon Corp (0.80%). Company insiders that own Insulet stock include Aiman Abdel-Malek, Bradley A Thomas, Charles Alpuche, David A Lemoine, David Colleran, John A Fallon, Michael L Levitz, Michael P Spears, Sally Crawford and Shacey Petrovic. View Institutional Ownership Trends for Insulet.

Which major investors are selling Insulet stock?

PODD stock was sold by a variety of institutional investors in the last quarter, including CSS LLC IL, Fred Alger Management LLC, Goldman Sachs Group Inc., Jennison Associates LLC, Eagle Asset Management Inc., Russell Investments Group Ltd., Marshall Wace North America L.P. and First Trust Advisors LP. Company insiders that have sold Insulet company stock in the last year include Aiman Abdel-Malek, Charles Alpuche, David A Lemoine, David Colleran, John A Fallon, Michael L Levitz, Michael P Spears, Sally Crawford and Shacey Petrovic. View Insider Buying and Selling for Insulet.

Which major investors are buying Insulet stock?

PODD stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Beacon Investment Advisory Services Inc., Sumitomo Mitsui Trust Holdings Inc., UBS Asset Management Americas Inc., Swiss National Bank, SG Americas Securities LLC, Cubist Systematic Strategies LLC and Trexquant Investment LP. View Insider Buying and Selling for Insulet.

How do I buy shares of Insulet?

Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Insulet's stock price today?

One share of PODD stock can currently be purchased for approximately $212.32.


MarketBeat Community Rating for Insulet (NASDAQ PODD)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  622 (Vote Outperform)
Underperform Votes:  545 (Vote Underperform)
Total Votes:  1,167
MarketBeat's community ratings are surveys of what our community members think about Insulet and other stocks. Vote "Outperform" if you believe PODD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PODD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel